11, 18, 25 February 2026

2° SYMPOSIUM

ON CANNABINOID
TRANSLATIONAL SCIENCE

11, 18, 25 February 2026

2° SYMPOSIUM

ON CANNABINOID
TRANSLATIONAL SCIENCE

WHY CANNABINOIDS?

The use of cannabinoids for medical purposes dates back more than 4,000 years. Originating from different sources (plant-derived, synthetically produced, or endogenously released), these molecules interact with, though are not limited to, cannabinoid receptors that are part of the endocannabinoid system. This complex cell-signaling system plays a key role in regulating many of the body’s critical functions.
Studying cannabinoids is crucial for advancing medical science and improving human health. Here, we aim to place the endocannabinoid system at the center of renewed international research and drug development efforts.

CANNABINOID TRANSLATIONAL SCIENCE

SYMPOSIUM

DISCOVER

FIRST SYMPOSIUM

CANNABINOIDS TRANSLATIONAL SCIENCE

DISCOVER

01

CHEMIST

By exploiting different areas (organic/medicinal/computational), the chemist can be considered the first pillar of the Route that drives research from the bench to the bedside. As a main actor, the chemist is the creator of new chemical entities that may become active drugs tackling diseases. By synthesizing ligands inspired by the reactivity of the molecules, aided by molecular docking and artificial intelligence algorithms, the chemist ultimately provides new strategies, more efficient and more stable, to combat diseases.

02

BIOCHEMIST

By exploiting different areas (cellular and molecular biology/pharmacology), the biochemist can be considered the second pillar of the Route that drives research from the bench to the bedside. As a main actor, the biochemist investigates the nature of binding between the new chemical entity (drug) and its targets and deepens the cellular mechanism of action. By investigating the interactions that new chemical entities may produce in our body, the biochemist ultimately provides the insights to formulate a drug and minimize the side effects.

03

CLINICIAN

By exploiting different areas (medicine/pathology/pharmaceutical regulatory), the clinical physician can be considered the third pillar of the Route that drives research from the bench to the bedside. As a main actor, the clinical physician leads clinical trials by adopting the chemical entities as a possible new therapy. By supporting ground-breaking research into new treatments ensuring patient safety, the clinical physician pioneers the next generation of medicines, and ultimately provides evidence to approve a drug on the market.